A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-Asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL).

Trial Profile

A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-Asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs ABT 751 (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Pegaspargase; Tioguanine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jul 2012 Actual patient number is 9 as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 29 Sep 2009 Planned end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top